Reteplase

• Product Name:Reteplase
• Synonyms: Reteplase Retavase Reteplase USP/EP/BP
• CAS:133652-38-7
• MF:
• MW:0
• EINECS:
• Mol File:Mol File
• 

Reteplase was launched in Germany and the US for acute myocardial infarction. Retevase is a single chain recombinant form of tissue plasminogen activator (t-PA) with all except the kringle-2 and protease domains deleted. When expressed in E. coli the inactive form is produced and stored in inclusion bodies. After purification and an in vitro refolding process the active form is obtained. The expression in E. coli gives rise to a non-glycosylated protein. This and the deletion of several domains allows reteplase to have a longer half-life and a slower clearance. Despite the deletions and refolding the catalytic center remains intact. The kringle-2 domain allows binding to lysine in fibrin which makes it effective for the rapid and complete lysis of coronary thrombi. While it does not have a high affinity for binding to fibrin, its activity is stimulated by it and has the same level of in vivo fibrin selectivity as human t-PA. It has a low affinity for endothelial cells and can be administered as a double bolus injection. Netaplase, a similar recombinant form of t- PA, was launched by MitsuiIMochida in Japan.

• Company Name:Dideu Industries Group Limited
• Tel:+86-29-89586680 +86-15129568250
• Products Intro:Product Name:Reteplase
  CAS:133652-38-7
  Purity:99.9% Package:25kgs/Drum;200kgs/Drum Remarks:FDA GMP CEP Approved Manufacturer
• CB Index:58
• Related Information:Catalog(22883)

• Company Name:TargetMol Chemicals Inc.
• Tel: 15002134094
• Products Intro:Product Name:Reteplase
  CAS:133652-38-7
  Package:100mg;50mg;25mg
• CB Index:58
• Related Information:Catalog(19711)